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Background. Lipoic acid (LA), which has signiﬁcant antioxidant properties, may also function as a potent neuroprotectant. The
synthetic compounds INV-155, INV-157, INV-159, and INV-161 are physiochemical combinations of lipoic acid and captopril.
We sought to determine if these compounds have neuroprotective potential following middle cerebral artery occlusion (MCAO)
in rats. Methods. Male Sprague-Dawley rats were injected intravenously with captopril (1–50mg/kg) 30 minutes prior to MCAO.
Blood pressure, heart rate, baroreceptor reﬂex sensitivity, and infarct size were measured. In addition, dose response eﬀect on
infarct size and cardiovascular parameters was determined using INV-155, INV-157, INV-159, and INV-161 and compared to
captopril and LA. Results. Pretreatment with captopril and LA at all doses tested was neuroprotective. The compounds INV-159
(0.5–10mg/kg) and INV-161 (1–10mg/kg) produced a signiﬁcant,dose-dependent decrease in infarct size. In contrast, INV-155
and INV-157 had no eﬀect on infarct size. Conclusions. Combined pretreatment with captopril potentiated the neuroprotective
beneﬁt observed following LA alone. Both INV-159 and INV-161 were also neuroprotective. These results suggest that patients
taking combinations of captopril and LA, either as combination therapy or in the form of INV-159 or INV-161, may also beneﬁt
from signiﬁcant protection against cerebral infarction.
1.Introduction
Hypertension prevalence is highly variable among popu-
lations worldwide. In the United States there is a dispro-
portionate burden of this disease and its complications in
African Americans [1]. African Americans have the highest
prevalence of hypertension in the world, signiﬁcantly higher
than people of African origin living outside the United States
[2]. According to the 2003-2004 National Health and Nutri-
tion Examination Survey (NHANES) hypertension preva-
lence is 39.1% in African Americans and 28.5% in White
Americans [3]. The increased prevalence of hypertension
in African-Americans has been attributed to both genetic
and environmental factors [4]. Additionally, hypertension is
usually observed at a younger age in African-Americans and
it resultsin more severe disease complications. This results in
a signiﬁcantly higher hypertension related mortality rate for
African Americans, 49.9% and 40.6% for African American
men and women, respectively, compared to 17.9% for the
overall US population in 2004 [1].
Cardiometabolic syndrome, a constellation of common
cardiovascular risk factors (obesity/overweight, atherogenic
dyslipidemia, glucose intolerance, and elevated blood pres-
sure) has been shown to directly increase atherosclerotic car-
diovascular disease [5]. Of particular interest is the im-
portant role of the endothelium in vascular homeostasis.
Endothelial changes are considered precursors to early chan-
ges in the atherosclerotic endothelium leading to chronic
diseases including cardiometabolic syndrome. Patients are
often prescribed antihypertensive drugs such as captopril in
an attempt to lower their risk for cardiovascular disease [6].
In addition, patients diagnosed with this syndrome would2 Cardiology Research and Practice
have a high probability of endothelial dysfunction and/or
biomarkers associated with these disorders. Anti-inﬂamma-
tory and antioxidant therapies have been shown to reduce
the biomarkers associated with this endothelial dysfunction
[7]. In fact, in a cross-over, double-blinded study in patients
diagnosed with cardiometabolic syndrome, our group has
recently demonstrated that one such naturally occurring
product α-lipoic acid (LA) improves endothelial function.
This eﬀect was potentiated in patients taking an angiotensin
converting enzyme (ACE) inhibitor similar to captopril [7].
Since both captopril [8, 9]a n dL A[ 10] have been shown to
provide neuroprotective eﬀects, we designed the current
study to determine if this combination therapy would also
provide neuroprotection. The results provide support for
our hypothesis that the combination of ACE inhibition and
LA may provide additional cerebrovascular protection in
patients with cardiometabolic syndrome.
2. Methods
All experiments were carried out in accordance with the
guidelinesoftheCanadianCouncilonAnimalCareandwere
approved by the University of Prince Edward Island’s Animal
Care Committee.
2.1. General Surgical Procedures. All experiments were con-
ducted on male Sprague-Dawley rats (200–350g; Charles
River; Montreal, PQ, Canada). For all animals, food and tap
water were available ad libitum. Rats were anaesthetized with
sodium thiobutabarbital (Inactin; Sigma-Aldridge; St. Louis,
MO, USA; 100mg/kg; i.p.) which provided a stable plane
of anesthesia for the full duration of the experimental time
periods (no animals required anesthetic supplementation).
To monitor blood pressure and heart rate, a polyethylene
catheter (PE-50; Clay Adams, Parsippany, NJ, USA) was in-
serted into the right femoral artery. For intravenous ad-
ministration of drugs a second polyethylene catheter (PE-
10; Clay Adams, Parsippany, NJ, USA) was inserted into the
right femoral vein. Arterial blood pressure was measured
with a pressure transducer (Gould P23 ID, Cleveland, OH)
connected to a Gould model 2200S polygraph. Heart rate
was determined from the pulse pressure using a Gould ta-
chograph (Biotach). These parameters were displayed and
analyzed using PolyviewPro/32 data-acquisition and analysis
software (Grass; Warwick, RI, USA). An endotracheal tube
was inserted to facilitate breathing. Body temperature was
monitored and maintained at 37 ± 1EC using a Physitemp
feedback system (Physitemp Instruments; Clifton, NJ, USA).
2.2. Middle Cerebral Artery Occlusions. Our research group
had previously published the detailed methodology for tran-
sient occlusion of the middle cerebral artery [11]. Brieﬂy,
animals were placed in a David Kopf stereotaxic frame
(Tujunga, CA, USA) and the right middle cerebral artery
(MCA) approached through a rostra-caudal incision of the
skin and frontalis muscle at the approximate level of bregma.
Blood ﬂow through the MCA was impeded by the placement
of surgical suture behind the MCA at 3 designated positions
along the exposed vessel. The ends of the sutures were posi-
tioned so that the middle of each suture applied pressure to
the MCA and completely impeded blood ﬂow as conﬁrmed
using laser Doppler ﬂowmetry (OxyFlo, Oxford-Optronix,
Oxford, UK). This 3-point placement of surgical sutures
producedahighlyreproducibleandconsistentfocalischemic
lesion restricted to the ipsilateral cerebral cortex. To facilitate
removal of the sutures at the end of the occlusion period (30
minutes), a few drops of warm physiological saline (37EC)
was ﬁrst applied to the areas where the MCA was in contact
with the sutures. Following removal of the sutures, blood
was allowed to reperfuse the area for an additional 5.5 hours
(I/R).
2.3. Cardiac Baroreﬂex Testing. To determine the eﬀect of
drug administration on the reﬂex bradycardia following
baroreceptor activation, the baroreceptor reﬂex was evoked
using a bolus intravenous injection of the α-adrener-
gic receptor agonist, phenylephrine-hydrochloride (Sigma-
Aldridge; St.Louis, MO, USA; 0.1mL; 2.5μg/mL; i.v.). The
ratioofthepeakchangeinthemagnitudeofthereﬂexbrady-
cardia to the magnitude of the phenylephrine-induced press-
or response (ΔHR/ΔM A P )w a su s e da sam e a s u r eo fb a r o r e -
ceptor sensitivity [12] (BRS). BRS was tested 10 minutes
and immediately prior to drug administration. BRS was then
tested15minutesfollowingdrugadministration(15minutes
prior to MCAO), and then 5, 10, and 20 minutes following
MCAO, as well as immediately prior to suture removal at 30
minutes. The BRS was also tested 30, 60, 90, 150, 210, 270,
and 330 minutes following suture removal.
2.4. Drug Development. The synthetic drugs INV-155, INV-
157, INV-159, and INV-161 were obtained from InVasc
Therapeutics Inc. (Atlanta, Georgia, USA). These are pat-
ented, proprietary drugs commercially available from InVasc
Therapeutics Inc., and are sold for the treatment of cardi-
ometabolic syndrome in humans. All of these compounds
are based on the physiochemical synthetic combination of
captopril and α-lipoic acid (LA) in a 1:1 ratio, but diﬀer in
their conﬁguration (derivatives of the parent compounds).
2.5. Eﬀect of Drug Administration on Infarct Volume, Blood
Pressure, Heart Rate, and BRS. In the ﬁrst experiment, to
examine the eﬀect of captopril on ischemic and reperfusion-
induced cell death, administration of captopril (Sigma-
Aldridge; St. Louis, MO, USA; 1, 5, 10, or 50mg/kg; 1mL/kg;
i.v.; n = 4 to 7/group) or physiological saline (0.9% sodium
chloride; 1mL/kg; i.v.; n = 5) was made 30 minutes prior to
theonsetofMCAO.Thirtyminutesfollowingdruginjection,
the sutures were put in place for 30 minutes, followed by 5.5
hoursofreperfusion.Infarctvolumewasmeasuredfollowing
5.5 hours of reperfusion and BRS was measured at the inter-
vals described above.
In the second experiment, a concentration of captopril of
5mg/kgwaschosenasitdidnotproduceasigniﬁcantchange
in blood pressure or heart rate, and was coadministered
in combination with various doses of lipoic acid (0.0005,
0.05 and 0.5mg/kg, 1mL/kg; i.v.; n = 6/group) which haveCardiology Research and Practice 3
been previously reported to have no signiﬁcant eﬀect on
infarct volume in the same MCAO model developed in our
laboratory [10]. This coadministration was done 30 minutes
prior to MCAO. Following 5.5 hours of reperfusion, BRS
were measured at the intervals described above and infarct
volume was determined.
Inthethirdexperiment,weaimedtodetermineifadmin-
istration of the combined drugs would result in a reduction
in infarct volume. Therefore, captopril (5mg/kg) and lipoic
acid (0.5mg/kg; 1mL/kg; i.v.) were coadministered immedi-
ately prior to the removal of the sutures (30 minutes after
MCAO) and infarct volume was measured following 5.5
hours of reperfusion.
Inthefourthexperiment,wecomparedtheeﬃcacyofthe
physiochemical combination of captopril-lipoic acid com-
pounds (INV-155, INV-157, INV-159, and INV-161; 10mg/
kg;1mL/kg;i.v.;n = 4or5pergroup)orvehicle(2%sodium
bicarbonate; 1mL/kg; i.v.; n = 4) administered 30 minutes
prior to MCAO followed by 5.5 hours of reperfusion. INV-
159 and INV-161 produced signiﬁcant neuroprotection and
were further studied to determine if the neuroprotection
was dose dependent. In addition to 10mg/kg, 0.1, 0.5, and
1mg/kg (1mL/kg; i.v.; n = 4/group) of INV-159 were ad-
ministered and 0.1 and 1mg/kg (1mL/kg; i.v.; n = 4/group)
of INV-161 were administered. Infarct volume and BRS was
determined as described above.
2.6. Eﬀect of Drug Administration on Blood Flow through the
MCA. To examine the eﬀect of systemic captopril, lipoic
acid, captopril-lipoic acid combinations, INV-159, and INV-
161 administration on cerebral blood ﬂow, we used laser
D o p p l e rﬂ o w m e t r yt om e a s u r eb l o o dﬂ o wb e f o r e ,d u r i n g
and following MCAO. Laser Doppler signals from the MCA
were recorded as relative values in blood perfusion units
(bpu).Thetipofa0.5mmprobe(OxyFlo,Oxford-Optronix,
Oxford, UK) was placed directly over the MCA just ventral
to the bifurcation of the MCA to the frontal and parietal
cortices. Warm physiological saline was applied to the area
so that the probe was measuring blood ﬂow through the
saline. Blood ﬂow through the MCA was measured at 10 and
5 minutes prior to drug administration, and then 5, 10, 15,
20, 30, and 60 minutes following drug administration.
2.7. Histological Procedures. At the end of each experiment
(total of 6 hours for each rat), all animals were perfused
transcardially with phosphate buﬀered saline (PBS; 0.1M;
200mls), the brains were removed and sliced into 1mm cor-
onal sections using a rat brain matrix (Harvard Apparatus;
Holliston, MA, USA). Sections were incubated in a 2% solu-
tion of 2,3,5-triphenol tetrazolium chloride (TTC; Sigma-
Aldrich; St. Louis; MO, USA) for 5 minutes. Infarct volumes
for both sides of each brain section were calculated with the
use of scanned digital images of each brain section and using
a computer-assisted imaging system (Scion Corporation;
Frederick, MD, USA). The sum total of all the individual
infarct volumes provided the total infarct volume for each
rat.
2.8. Statistical Analysis. Data were analyzed using a sta-
tistical software package (SigmaStat and SigmaPlot; Jandel
Scientiﬁc, Tujunga, CA). All data are presented as a mean
± standard error of the mean (S.E.M.). Diﬀerences were
considered statistically signiﬁcant if P ≤ 0.05 by a one-way
analysis of variance (ANOVA) followed by a Bonferroni post
hoc analysis. When only two groups were being compared,
Student’s t-test was used.
3. Results
3.1. The Eﬀect of Preadministration of Captopril on Infarct
Volume. The following experiment was designed to deter-
mine the eﬀect of captopril pretreatment on MCAO-induced
ischemia/reperfusion (I/R) injury. Captopril was adminis-
tered 30 minutes prior to suture placement and infarct
volume was measured following 5.5 hours of reperfusion.
Captopril pre-treatment did not result in signiﬁcant neuro-
protection compared to saline with any of the doses tested
(P ≥ 0.05; Figures 1(a) and 1(b)).
3.2. The Eﬀect of Preadministration of the Combination of
Captopril and Lipoic Acid on Infarct Volume. The following
experiment was designed to determine the eﬀect of coad-
ministration of captopril with previously reported nonneu-
roprotective doses of lipoic acid on MCAO-induced ische-
mia/reperfusion (I/R) injury. The drug combinations were
administered 30 minutes prior to suture placement and in-
farct volume was measured following 5.5 hours of reperfu-
sion.Combining captopril(5mg/kg)witheachdoseoflipoic
acid (0.005, 0.05, and 0.5mg/kg) resulted in signiﬁcant neu-
roprotection compared to saline (P ≥ 0.05; Figure 2).
3.3. The Eﬀect of Postadministration of the Drug Combination
of Captopril and Lipoic Acid on Infarct Volume. The follow-
ing experiment was designed to determine the eﬀect of the
co-administration of captopril and lipoic acid on MCAO-
induced ischemia/reperfusion (I/R) injury. Co-administra-
tion of the drug combination immediately prior to suture
removal (30 minutes post-MCAO) did not result in a signif-
icant change in infarct volume compared to the administra-
tion of saline (P ≥ 0.05; Figure 3).
3.4. The Eﬀect of Preadministration of the Compounds INV-
155,INV-157,INV-159,andINV-161onInfarctVolume. The
following experiment was designed to determine the neuro-
protective capacity of the designer drugs INV-155, INV-157,
INV-159, and INV-161 on MCAO-induced ischemia/reper-
fusion (I/R) injury. Each drug was administered 30 minutes
prior to suture placement and infarct volume was measured
following 5.5 hours of reperfusion. INV-155 (10mg/kg) and
INV-157 (10mg/kg) did not result in significant neuro-
protection compared to sodium bicarbonate vehicle (P ≥
0.05; data not shown). However, INV-159 (10mg/kg) and
INV-161(10mg/kg)didresultinsigniﬁcantneuroprotection
compared to sodium bicarbonate vehicle and therefore
completedose-responsecurvesweregeneratedforeachdrug.
INV-159 produced signiﬁcant neuroprotection using doses4 Cardiology Research and Practice
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Figure 1: (a) Representative photomicrographs of TTC stained, 1mm thick coronal slices illustrating the extent of the infarct within the
prefrontal cortex following 30 minutes pretreatment (i.v.) with either saline or captopril (5.0mg/kg) and ischemia/reperfusion (I/R). (b)
Eﬀect of pretreatment with either saline or captopril on infarct volume (mm3) calculated from TTC-stained 1mm thick coronal sections
throughout the extent of the infarct following I/R and pretreatment (i.v.; 30 minutes) with either saline or captopril. Each bar represents the
mean ± S.E.M (n = 4–7/group).
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Figure 2: Eﬀect of pretreatment (30 minutes before MCAO) with
either saline (n = 5) or co-administration of captopril and lipoic
acid (n = 6/group) on infarct volume (mm3)c a l c u l a t e df r o mT T C -
stained Imm thick coronal sections throughout the extent of the
infarct following I/R. Each bar represents the mean ± S.E.M. and
∗indicates signiﬁcance (P ≤ 0.05) from the saline control group
(n = 4–7/group).
of 0.5, 1.0, and 10mg/kg (Figure 4(a); P ≤ 0.05 for each
dose) and INV-161 produced signiﬁcant neuroprotection
using doses of 1.0, and 10mg/kg (Figure 4(b); P ≤ 0.05 for
each dose).
3.5. The Eﬀect of Drug Preadministration on Cardiovascular
Parameters. The following experiments were designed to
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Figure 3: Average infarct volume (mm3) following either saline
(n = 6) or a combination of captopril (5mg/kg) and lipoic acid
(0.5mg/kg; n = 4) administration (i.v.) immediately prior to suture
removalandthebeginningofreperfusion(30minutesafterMCAO)
calculated from TTC-stained coronal sections throughout the ex-
tent of the infarct. Each bar represents the mean ± S.E.M.
determine the eﬀect of drug preadministration on blood
pressure, heart rate, and BRS before and following 30
minutes of MCA occlusion. Preadministration of captopril
(1.0mg/kg and 5mg/kg) or saline did not signiﬁcantly alter
mean blood pressure or mean heart rate prior to, during,
or following occlusion (P>0.05; n = 4-5/dose; data not
shown). However, the administration of captopril (10 and
50mg/kg) resulted in a transient decrease in mean arterialCardiology Research and Practice 5
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Figure 4: (a) Eﬀect of pretreatment with either 2% sodium bicarbonate (vehicle), INV-159, or INV-161 (b) on infarct volume (mm3)
calculated from TTC-stained 1mm thick coronal sections throughout the extent of the infarct following I/R. Each bar represents the mean
± S.E.M. and ∗indicates signiﬁcance (P ≤ 0.05) from the vehicle control group (n = 4-5/group).
pressure by 19 ± 5a n d3 4± 11mmHg, respectively, (from
an average baseline of 113 ± 9mmHg) for ∼5 minutes. This
hypotensive eﬀect was accompanied by a reﬂex tachycardia
of 9±2a n d1 9 ±6 beats/min(fromanaveragebaselineheart
rate of 412±23 beats/min. When the BRS was tested follow-
ingreturnofthecardiovascularparameterstobaselinevalues
5 minutes after captopril injection, there was no significant
diﬀerence compared to the preinjection value (0.55 ± 0.1
versus 0.5 ±0.2).
Co-administration of captopril (5mg/kg) with lipoic ac-
id (doses 0.005, 0.05, and 0.5mg/kg) 30 minutes prior to
MCAO did not signiﬁcantly alter mean arterial pressure,
mean heart rate, or BRS prior to, during, or following oc-
clusion compared to saline vehicle (P>0.05; n = 5; data not
shown). Administration of INV-159 (10mg/kg) or INV-161
(10mg/kg) did not signiﬁcantly alter mean arterial pressure,
mean heart rate, or BRS prior to, during, or following occlu-
sion compared to vehicle (2% sodium bicarbonate; P>0.05;
n = 4/group; data not shown).
3.6. Eﬀect of Drug Administration on Blood Flow through the
MCA. ToquantifybloodﬂowthroughtheMCAbefore,dur-
ing, and following occlusion, we used laser Doppler ﬂowme-
try (Figure 4(b)). Administration of captopril (5mg/kg),
INV-159 (10mg/kg) or INV-161 (10mg/kg) 30 minutes pri-
or to MCA occlusion did not result in signiﬁcant changes in
blood ﬂow compared to preadministration values (P>0.05;
n = 4-5/drug; data not shown).
4. Discussion
The present investigation was conducted to determine if
combination therapy using two known compounds, capto-
p r i la n dl i p o i ca c i d( L A )a l r e a d yp r e s c r i b e da n du s e db y
humans for the treatment of symptoms associated with car-
diometabolic syndrome, could provide beneﬁcial eﬀects
against cerebrovascular disease. The results of the present
study supported our hypothesis that these drugs, in com-
bination or synthetically combined, provide signiﬁcant neu-
roprotection in a rat stroke model. In addition, no adverse
cardiovascular complications were observed following pre-
treatment with any of these drugs, nor did they reverse the
autonomic dysfunction observed following MCAO.
Cardiovascular and metabolic diseases (including athe-
rosclerosis, stroke, and diabetes mellitus) represent the single
largest global pharmaceutical opportunity within the phar-
maceutical industry. The annual prescription drug revenue
in this cardiometabolic space now exceed $400 billion an-
nually. The advancing age of baby boomers, increased world-
wide incidence of obesity, and a transition to a Western
diet in much of the developing world clearly suggests that
these chronic diseases will continue to be a primary driver
within the industry. Cardiovascular and metabolic diseases
represent huge product opportunities. However, the FDA
have been driven by safety concerns and responding to con-
gressional pressures associated with drug safety and eﬃcacy
beneﬁt and the rising impact of healthcare on the gross
domestic product. As a result, the agencies have become
more restrictive in deﬁning acceptable clinical endpoints.
Furthermore, they are reducing the acceptance on surrogate
endpoints in phase III trials designed for product approval.
We believe that combining known nutraceuticals, such as
LA, with approved prescription drugs (such as captopril)
to magnify clinical beneﬁts oﬀer a signiﬁcant development
advantage and expedites the regulatory process for novel
drug discovery.
In terms of the advantage of combination therapy, our
results show that captopril signiﬁcantly potentiated the neu-
roprotective eﬀects of LA. Since captopril did not aﬀect in-
farct volume or cerebral blood ﬂow alone, it may not have fa-
cilitated access of LA to the brain. Therefore, the exact mech-
anism of this synergistic interaction requires further investi-
gation.6 Cardiology Research and Practice
In conclusion, our results support a role for the combi-
nation of captopril and LA to provide potential neuroprotec-
tion, and that this strategy of combination therapy for novel
drug discovery should be further exploited.
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